๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Prognostic significance of COX-2 expression in advanced head and neck cancer treated with radiotherapy in a phase III RTOG trial (90-03)

โœ Scribed by K.K. Ang; B.A. Berkey; A.T. Koki; J.L. Harmon; M.E.H. Hammond; K.K. Fu; J.S. Cooper; L. Milas

Book ID
117657986
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
183 KB
Volume
37
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

p53 and P-glycoprotein expression are si
p53 and P-glycoprotein expression are significant prognostic markers in advanced head and neck cancer treated with chemo/radiotherapy
โœ Warnakulasuriya, Saman; Jia, Chaoying; Johnson, Newell; Houghton, Joan ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 117 KB ๐Ÿ‘ 2 views

The development of biological markers of response to chemo-and radiotherapy to judge beneยฎt to risk ratios for toxic treatments is still at an experimental stage. Tumour cell death is largely by apoptosis and the p53 gene has a major inยฏuence on this. P-glycoprotein (P-gp) accumulation has been corr

Impact of nutrition support on treatment
Impact of nutrition support on treatment outcome in patients with locally advanced head and neck squamous cell cancer treated with definitive radiotherapy: A secondary analysis of RTOG trial 90-03
โœ Rachel Rabinovitch; Barbara Grant; Brian A. Berkey; David Raben; Kie Kian Ang; K ๐Ÿ“‚ Article ๐Ÿ“… 2006 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 163 KB ๐Ÿ‘ 1 views

## Background: The aim was to evaluate the relationship between nutrition support (ns) on host toxicity and cancer outcome in patients with locally advanced head and neck squamous cell carcinoma (hnscc) undergoing definitive radiotherapy (xrt). ## Methods: We performed a secondary analysis of rad

Neurotoxicity in a phase I trial of cont
Neurotoxicity in a phase I trial of continuous-infusion cisplatin with hyperfractionated radiotherapy for locally advanced head and neck cancer
โœ Gerald H. Clamon; Lynn Baatz; Henry T. Hoffman; David H. Hussey; Matthew Glascoc ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 569 KB

## Background: Both twice daily fractionated radiotherapy and concurrent cisplatin with once-daily radiotherapy have been shown to improve local disease control in patients with head and neck cancer. the objective of this phase i trial was to determine the maximum tolerated dose of cisplatin which